| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9155278 | American Heart Journal | 2005 | 7 Pages |
Abstract
The CHARISMA trial will further characterize atherothrombosis and provide insight into the role of dual antiplatelet therapy in improving outcomes in patients with multiple risk factors or established vascular disease. Of note, the rates of obesity and diabetes in patients with atherothrombosis throughout the world are particularly alarming.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Deepak L. MD, Keith A. MBChB, FRCP, Werner MD, Peter B. MD, Henry R. MD, William E. MD, Patrice MD, Eric A. MD, Mark A. MD, J. Donald MD, Marcus D. MD, Steven M. MD, Christian W. MD, Graeme J. MD, S. Claiborne MD, Koon-Hou MD, Jean-Louis MD, Gilles MD,